IP Library › Granted Patent US 9,657,340
Granted Patent B2
US 9,657,340 · App. 14/709,793 · Granted May 23, 2017

Isothermal nucleic acid amplification

Inventor: Mark Jay Hoser (Broadstairs, GB)
Assignee: ORION PHARMA (UK) LIMITED
C12Q1/6844
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,657,340
App. No.
14/709,793
Granted
May 23, 2017
Kind
B2
Abstract

A kit for performing isothermal amplification of a nucleic acid target molecule, where the amplification relies on an upstream primer, a downstream primer, a strand invasion system and an oligonucleotide, wherein the upstream and downstream primers are not substrates for the strand invasion system during the amplification process and do not amplify the target molecule independently of the strand invasion system, wherein the oligonucleotide is a substrate for the strand invasion system.

Claims (18)

1. A kit for isothermal amplification of a double-stranded nucleic acid target molecule, the kit comprising:

(i) a recombinase;

(ii) an upstream nucleic acid primer and a downstream nucleic acid primer that do not bind the double-stranded nucleic acid target molecule, are not substrates for the recombinase, and do not amplify the target molecule independently of the recombinase, wherein each of said upstream and downstream nucleic acid primers comprises a single-stranded DNA molecule of less than 25 nucleotides, wherein at least a portion of each nucleic acid primer is complementary to a sequence of the target molecule; and

(iii) an oligonucleotide comprising a single-stranded DNA molecule of at least 30 nucleotides, at least 24 of said nucleotides of said oligonucleotide are complementary to the target molecule in a region between upstream and downstream nucleic acid primer binding sites, and at least a portion of the oligonucleotide is substrate for the recombinase.

2. The kit of claim 1 , wherein the oligonucleotide has a non-extendable 3′ terminus.

3. The kit of claim 1 , wherein the recombinase is UvsX.

4. The kit of claim 3 , further comprising at least one recombinase accessory protein.

5. The kit of claim 1 , wherein each of the upstream and downstream nucleic acid primers comprises a single-stranded DNA molecule of 12 to 24 nucleotides.

6. The kit of claim 5 , wherein the at least one recombinase accessory protein is gp32.

7. The kit of claim 5 , wherein the at least one recombinase accessory protein is UvsY.

8. The kit of claim 1 , wherein the oligonucleotide comprises a downstream element at its 3′ terminus which is complementary to the target molecule and which is not a polymerase substrate.

9. The kit of claim 1 further comprising a strand displacing polymerase.

10. The kit of claim 1 , wherein the upstream nucleic acid primer comprises a sequence which overlaps with the oligonucleotide.

11. The kit of claim 10 , wherein 5 to 10 nucleotides of a terminus of the upstream nucleic acid primer overlap with the oligonucleotide.

12. The kit of claim 8 , wherein the downstream nucleic acid primer comprises a sequence which is complementary to a sequence of the downstream element of the oligonucleotide.

13. The kit of claim 1 , wherein 24 to 63 nucleotides of the oligonucleotide is complementary to the target molecule.

14. The kit of claim 1 , wherein each of the upstream and downstream nucleic acid primers comprises a single-stranded DNA molecule of 12 to 25 nucleotides.

15. The kit of claim 14 , wherein each of the upstream and downstream nucleic acid primers comprises a single-stranded DNA molecule of 15 to 23 nucleotides.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2018
From: ORION PHARMA (UK) LIMITED
To: GENEFORM TECHNOLOGIES LIMITED
Reel/Frame 045351/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2015
From: GENEFORM TECHNOLOGIES LIMITED
To: ORION PHARMA (UK) LIMITED
Reel/Frame 036691/0928 →
Priority Claims (2)
GB 0810650.2 · Jun 11, 2008 · national
GB 0822533.6 · Dec 11, 2008 · national
Continuity (2)
Division 12997382
Related Publication 20150307928A1 · Oct 29, 2015